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COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial
Effect of Inhaled Corticosteroids?
Coronavirus disease (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a
real pandemic. After a median incubation period of 5 days, the
disease occurs in different stages, inducing upper and lower airway
responses in mild disease (80–90% of patients) and progressing to
bilateral pneumonia in severe disease (10–20%) (1–3). A subgroup
of patients with severe COVID-19 develops acute respiratory
distress syndrome, requiring mechanical ventilation on intensive
care. COVID-19 patients with preexisting comorbid conditions
such as chronic respiratory diseases have worse disease outcomes,
including a higher incidence of the need for hospitalization, ICU
admission, and mortality (3, 4). However, it remains to be further
investigated how preexisting chronic inflammatory airway diseases,
such as asthma and chronic obstructive pulmonary disease
(COPD), and their treatment might modify the risk for SARS-
CoV-2 infection and development of COVID-19. Approximately
300 million individuals worldwide have asthma (5). Considering
that a significant proportion of individuals with asthma is
confronted with COVID-19, it is crucial to understand which
asthma patients are particularly at risk and how inhaled
corticosteroids (ICS)—the cornerstone of asthma treatment—may
influence morbidity and mortality associated with COVID-19.
Long-term treatment with systemic corticosteroids (e.g., in
transplant patients) is immunosuppressive, increasing the risk
and severity of viral infections. Because of the potential risk for
worse disease outcomes, the World Health Organization does
not recommend systemic corticosteroid treatment in COVID-19
(6), unless if indicated for other reasons such as acute asthma
or COPD exacerbations requiring a short course of oral
corticosteroids. These recommendations have caused doubt
and uncertainty among patients with asthma and physicians
on whether ICS therapy should be maintained during this
pandemic. However, withdrawal of ICS treatment puts
asthma patients at risk of severe exacerbations. A recent
meta-analysis on COVID-19 outcomes in patients with
chronic respiratory diseases using ICS concluded that there
is currently insufficient evidence to abandon the well-
established ICS treatment in asthma (7). There is thus
an urgent need to elucidate demographic and clinical
characteristics that determine disease outcomes of COVID-19
in asthma, to investigate the impact of ICS and to unravel the
underlying pathogenic mechanisms.
In this issue of the Journal, the elegant study by Peters and
colleagues (pp. 83–90) provides important insights in the complex
interplay between asthma, ICS, SARS-CoV-2 infection and
COVID-19 (8). The authors hypothesized that differences in the
expression of ACE2 (angiotensin-converting enzyme 2) and
TMPRSS2 (transmembrane protease serine 2) may modulate the
individual susceptibility to and clinical course of SARS-CoV-2
infection and thus identify asthma subgroups at risk for COVID-
19 morbidity. Whereas the spike protein of SARS-CoV-2 binds to
ACE2 as receptor during viral attachment to host cells, viral entry
is also facilitated by priming of the spike protein by the
membrane-bound protease TMPRSS2 (9). By investigating
induced sputum samples from 330 participants of the SARP-3
(Severe Asthma Research Program-3) program, a large and well-
characterized cohort of asthma subjects (60% severe asthma) and
79 healthy controls, Peters and colleagues made three major
discoveries. First, they found that there were no significant
differences in gene expression of ACE2 in sputum between asthma
and healthy subjects, suggesting that asthma subjects might not be at
increased risk of COVID-19. This contrasts with the increased
expression of ICAM-1 (intercellular adhesion molecule 1) in sputum
of asthmatics. ICAM-1 is the receptor for rhinovirus, which causes
only limited upper airway symptoms in healthy individuals, but can
elicit protracted lower airway symptoms and severe exacerbations in
asthmatics. Second, they discovered that male sex, African American
ethnicity, and a history of diabetes mellitus are associated with an
elevated ACE2 and TMPRSS2 mRNA expression in induced sputum.
Because people with diabetes have worse outcomes in severe
COVID-19 (2, 3, 10), these findings suggest that increased expression
of SARS-CoV-2–associated genes may facilitate viral infection and
underscore that asthmatics with one or more of these characteristics
should be monitored for worse outcomes of COVID-19.
Third and most importantly, they demonstrate that—in
contrast to systemic corticosteroids—the use of ICS in asthma
subjects was dose-dependently associated with reduced ACE2 and
TMPRSS2 mRNA expression. If these intriguing findings are
confirmed at the protein level, they may have important clinical
implications. ACE2 expression has been predominantly reported
in epithelial cells (11–13), which are a minor fraction within
induced sputum, which mainly samples inflammatory cells in the
lower airways. How expression of SARS-CoV-2–associated genes
is modulated in specific airway inflammatory cells in asthma and
whether this affects viral entry and infectivity require further
investigation. Moreover, it is important to evaluate the expression
of ACE2 also in lung tissue since this is the predominant place of
injury in severe COVID-19. In our lung tissue bank at Ghent
University Hospital, we studied ACE2 gene expression in lung
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resection specimens of white subjects with and without obstructive
airway disease (OAD), encompassing asthma and/or COPD,
and investigated whether ACE2 gene expression was associated
with ICS use (Figure 1). Whereas ACE2 mRNA expression in
lung tissue was significantly increased in (current or former)
smokers with COPD, it was not altered in subjects with asthma
or asthma–COPD overlap (ACO) as compared with controls
without OAD (Figure 1A). However, pulmonary gene expression
of ACE2 did not differ in ICS-treated and non–ICS-treated
OAD subjects (Figure 1B). These results need to be replicated
in larger prospective studies and in other (nonwhite) ethnicities.
The divergent effects of ICS use on ACE2 expression between
both studies might be due to differences in respiratory
compartment (induced sputum vs. lung tissue) or patient
population (nonsmoking patients with asthma vs. smokers
with COPD).
In conclusion, the crucial findings from Peters and colleagues
support the recommendation that in patients with asthma using ICS,
this treatment should be continued since ICS are the cornerstone
of asthma management, reducing exacerbations and asthmamortality,
and are associated with decreased expression of ACE2, the receptor
of SARS-CoV-2, in induced sputum. To what extent up- or
downregulation of ACE2 expression in sputum, airways, or lungs
has clinical consequences on infectivity or outcomes of COVID-19
needs to be elucidated. In subjects without asthma (or exacerbation-
prone COPD), ICS should not be started since ICS use does
not seem to influence ACE2 expression in lung tissue. However,
we eagerly await the results of randomized controlled trials
assessing the efficacy and safety of ICS in treating COVID-19
in patients with and without chronic airway diseases
(see https://clinicaltrials.gov). n
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Figure 1. ACE2 (angiotensin-converting enzyme 2) mRNA expression in human lung tissue and effect of ICS. (A) ACE2 gene expression in lung tissue
from controls (n=61), asthma/ACO (n=7), and COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) (n=38). (B) ACE2 gene
expression in controls (no OAD, no ICS use, n=56), in subjects with OAD not using ICS (n=23) and in subjects with OAD using ICS (n=25). Lung
resection samples were obtained with approval from the ethical committee of Ghent University Hospital (2016/0132); all participants provided written
informed consent. Processing for RNA and quantitative RT-PCR analysis was performed as described previously (14, 15). ACE2 mRNA expression was
normalized to the expression of three reference genes. ACO=asthma–COPD overlap; COPD=chronic obstructive pulmonary disease; ICS= inhaled
corticosteroids; OAD=obstructive airway diseases (asthma, ACO, or COPD).
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Personalized Blood Pressure Targets in Shock: What If Your Normal
Blood Pressure Is “Low”?
The cornerstone of resuscitation of septic shock is volume infusion
followed by vasopressors if fluid volume does not restore adequate
perfusion (1). Surviving Sepsis Campaign guidelines recommend
an initial target mean arterial pressure (MAP) of 65 mm Hg (1),
subsequently adjusted. The target MAP and the relative
proportions of use of volume versus vasopressors varies widely
(2, 3). But there remains the overarching large question of how to
personalize a MAP target in shock (Figure 1).
In patients with hypertension, targeting a higher MAP
(80–85 mm Hg) was associated with enhanced renal function but
not with lower mortality (4). There are no large studies regarding
resuscitation of patients with naturally low blood pressure. Do we
resuscitate to 65 mm Hg? Would we use excessive vasopressors and
increase organ dysfunction and mortality?
In this issue of the Journal, Gershengorn and colleagues (pp.
91–99) determined an inverse relationship between premorbid
systolic arterial pressure (SAP) with dose and duration of
vasopressors in shock in a single healthcare system cohort
(n= 4,689, from 2012 to 2018) (5). Patients were classified as
having low blood pressure (SAP, 100 mm Hg), normal blood
pressure (SAP 100–139 mm Hg), or high blood pressure
(SAP. 140 mm Hg) before shock. The actual MAP during
vasopressor infusion was lower in the group with low SAP than in
the groups with normal and high SAP (Table 1). We do not know
the MAP targets of these groups. Patients with low SAP were
treated for longer with higher doses of norepinephrine and had
greater ICU length of stay (LOS) and higher mortality. There was
no association of premorbid blood pressure and duration of
vasopressors with renal replacement therapy (RRT); one might
have expected greater duration of RRT if renal function had
worsened because of overuse of vasopressors.
The results were robust and consistent across subgroups.
These authors tested a very relevant clinical question and used
strong analytic methods, and the study’s implications are
important. The study was of a large, single healthcare system
cohort, limiting the interpretation of generalizability and
causality. It would have been insightful to examine
cardiovascular outcomes such as arrhythmias (especially atrial
fibrillation), stroke (new-onset atrial fibrillation was associated
with the higher MAP target group in Asfar and colleagues [6],
and new-onset atrial fibrillation is associated with stroke in
septic shock [7]), and acute myocardial infarction. These data
would further strengthen the argument that the higher dose and
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